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Abstract
Background: MicroRNAs are important regulators of transcription in hematopoiesis. Their expression deregulations
were described in association with pathogenesis of some hematological malignancies. This study provides
integrated microRNA expression profiling at different phases of chronic myeloid leukemia (CML) with the aim to
identify microRNAs associated with CML pathogenesis. The functions of in silico filtered targets are in this report
annotated and discussed in relation to CML pathogenesis.
Results: Using microarrays we identified differential expression profiles of 49 miRNAs in CML patients at diagnosis,
in hematological relapse, therapy failure, blast crisis and major molecular response. The expression deregulation of
miR-150, miR-20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-181a, miR-221 and miR-222 in CML was
confirmed by real-time quantitative PCR. In silico analyses identified targeted genes of these miRNAs encoding
proteins that are involved in cell cycle and growth regulation as well as several key signaling pathways such as of
mitogen activated kinase-like protein (MAPK), epidermal growth factor receptor (EGFR, ERBB), transforming growth
factor beta (TGFB1) and tumor protein p53 that are all related to CML. Decreased levels of miR-150 were detected
in patients at diagnosis, in blast crisis and 67% of hematological relapses and showed significant negative
correlation with miR-150 proved target MYB and with BCR-ABL transcript level.
Conclusions: This study uncovers microRNAs that are potentially involved in CML and the annotated functions of
in silico filtered targets of selected miRNAs outline mechanisms whereby microRNAs may be involved in CML
pathogenesis.
Introduction
Mammalian microRNAs (miRNA, miR) are short non-
coding RNAs that regulate preferentially gene expression
by inhibiting translation of specific target mRNAs.
MiRNA-mRNA matching is based on imperfect
sequence base-pairing with the required complementar-
i t yc e n t e r e do v e rp o s i t i o n s2-8o fm R N A ’ss e e d
sequence [1]. Depending on specific target genes, miR-
NAs regulate many cellular functions such as develop-
mental timing, signal transduction, apoptosis, cell
proliferation and tumorigenesis [2-5]. Thus, gene
expression and role of miRNAs are currently being lar-
gely studied in human malignancies and chemical com-
pounds that regulate miRNA levels are potentially very
important for developing new treatment strategies in
chronic myeloid leukemia (CML). The first miRNA
molecules that have been associated with human leuke-
mia pathogenesis were found in chronic lymphocytic
leukemia (CLL) [6]. MiR-15 and miR-16 are located in a
genomic region that is frequently deleted in CLL, thus
the expression of these two miRNAs is downregulated.
Other works brought the evidence that many miRNAs
are indeed found at chromosomal breakpoints and
genomic regions associated with cancer [7,8].
In CML the following miRNAs were associated with
the disease pathogenesis. For instance, the miR-203 was
found to be epigenetically silenced in human leukemic
Philadelphia chromosome-positive (Ph+) cell lines; this
is in line with the observation that BCR-ABL and ABL
kinases are miR-203 putative targets [9]. Derivative 9q+
chromosome deletions carrying miR-199b that occurred
in some CML patients were associated with miR-199b
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cluster (onkomir-1) to be aberrantly expressed in CD34
+ cells of CML patients. Agirre at al. [12] analyzed the
expression of 157 miRNAs in mononuclear and CD34+
cells separated from bone marrow of 6 CML patients at
diagnosis and found 11 miRNAs (e.g. miR-150, miR-
151, miR-221, miR-127, miR-16) aberrantly expressed in
CD34+ cells and 53 miRNAs differentially expressed in
mononuclear cells (e.g. miR-150, miR-126, miR-221,
miR-222, miR-21). Two recent works contributed to the
knowledge about expression change in specific micro-
RNAs associated with resistance to imatinib or respon-
siveness to imatinib after the treatment initiation in
CML patients [13,14]. A group of 19 miRNAs (e.g. miR-
191, miR-29a, miR-422b, miR-100, miR-326, miR-26a)
were identified as possible predictors for clinical resis-
tance to imatinib in patients with newly diagnosed CML
[13]. A relatively rapid increase in the expression of
miR-150 and miR-146a and decrease of miR-142-3p and
miR-199b-5p in peripheral blood mononuclear cells
(PBMCs) of patients newly diagnosed with CML was
found two weeks after imatinib initiation [14].
In this study, we used an array platform to character-
ize differentially expressed miRNAs in peripheral blood
total leukocytes of patients at different stages of CML
including diagnosis, major molecular response, therapy
failure, hematological relapse, accelerated phase and
blast crisis with the aim to identify microRNAs asso-
ciated with pathogenesis of CML. To the best of our
knowledge, such integrated microRNA profiling during
the course of CML has not yet been performed. Hier-
archical clustering analysis based on expression profiles
of 49 miRNAs clearly separated patients at diagnosis,
hematological relapse and blast crisis from those in
major molecular response and therapy failure. We used
in silico analyses to better understand the targets of 17
selected miRNAs whose deregulation was confirmed by
real-time quantitative PCR (RT-qPCR). Based on our
previous results demonstrating that miR-150 downregu-
lation is associated with CML [15], we further validated
miR-150 expression in a larger number of patients (n =
70). As MYB represents functionally validated target of
miR-150 [16], its gene expression analysis was per-
formed on the same patient cohort. Our data provide
significant inverse correlations between miR-150 and
MYB expression and BCR-ABL transcript level and indi-
cate that this relationship is potentially important for
pathogenesis in CML.
Materials and methods
Patient samples
Twenty four patient samples of total leukocytes from
peripheral blood (Table 1) were used to prepare pools
representing different CML phases for microarray
analysis: diagnosis (n = 5, Dg), major molecular response
(n = 5, MMR), therapy failure (n = 5, TF), hematological
relapse (n = 5, Hr), and blast crisis (n = 4, BC). Briefly,
Dg, Hr and BC contain 100% of Ph+ cells. Therapy fail-
ure is defined here as complete hematological response
with failure to achieve complete cytogenetic remission
(CCgR). Hematological relapse is defined as increased
number of WBC (range 14-28*10
9/L). MMR samples are
characterized as BCR-ABL <0.1% (IS). BC samples con-
tain blast cells in peripheral blood from 50% to 79%.
Eleven healthy donors of age median 60 (range 45 - 78)
and man/woman ratio 3/2 following CML incidence
were used to create a control pool.
Seventy patient samples of total leukocytes from per-
ipheral blood were used for miR-150 expression valida-
tion and MYB expression analyses (Table 2). Of these,
13 represented Dg, 16 = MMR, 14 = TF, 15 = Hr and
12 = AP (accelerated phase) together with BC (AP/BC).
Therapy failure is defined here as non CCgR achieve-
ment; all patients achieved complete hematological
remission and two patients major and minimal cytoge-
netic response, respectively. Hematological relapse is
characterized by increased number of WBC and PLT
(median 16*10
9/L and 448*10
9/L, respectively).
The percentage of BCR-ABL transcript level was
observed from the routine monitoring using real-time
qPCR that is standardized within the frames of interna-
tional standardization [17]. Mutation analyses were per-
formed by direct sequencing method [18].
All subjects donated their samples with informed con-
sent approved by the Ethic Committee of the Institute
of Hematology and Blood Transfusion, Prague.
Sample preparation
Cell pooling was applied for microarray analysis at the
aim to reduce individual variability and to find common
features of the disease stage. Pooling strategy was per-
formed according to previously described recommenda-
tions [19,20]. Pools consisted of five patient samples; the
blast crisis pool contained only four samples due to lack
of appropriate material. Samples were selected for pool-
ing according to their similar characteristics listed in
Table 1. Each patient contributed to the pool by the
same amount of leukocytes (10
7).
RNA extraction
Two different approaches were initially tested to extract
total RNA containing small RNA molecules: acidic phe-
nol-chloroform procedure and miRVana kit (Ambion
®,
Applied Biosystems, Foster City, CA, USA). The quality
and quantity of RNA were evaluated using Agilent 2100
Bioanalyser (Agilent Technologies, Santa Clara, CA,
USA) and spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA), respectively. The miRVana kit
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Pools Patient
number
(gender)
IM
therapy
(months)
WBC
count
(*10
9/L PB)
Thrombocyte
count
(*10
9/L PB)
Blast
count
(% in PB)
BCR-
ABL
(%)
Ph+
cells
(%)
Pretreatment BCR-ABL
mutations
Dg 1 (F) 0 71.4 749 0 60 100 HU NA
2 (F) 0 66.5 824 3 131 100 HU NA
3 (M) 0 22.3 509 1 144 100 HU NA
4 (M) 0 15.5 636 0 312 100 HU NA
5 (M) 0 198.5 550 1 139 100 HU, IFN NA
MMR 6 (M) 14.8 5.7 244 0 0.001 0 HU NA
7 (F) 7.4 5.3 153 0 0.01 0 HU NA
8 (M) 9.2 6.1 181 0 0.001 0 HU NA
9 (M) 19.6 4.2 309 0 0.04 0 HU NA
10 (M) 13.1 4.8 230 0 0.02 0 HU NA
TF 11 (F) 17.6 4.8 224 0 37 90 IFN M351T
12 (M) 14.3 4.2 142 0 15 100 HU WT
13 (F) 15.1 5.4 252 0 37 30 HU WT
14 (F) 13.5 2.4 100 0 23 60 HU, IFN WT
15 (M) 13.1 4.5 171 0 38 100 HU WT
Hr 16 (M) 13.6 28.1 448 0 80 100 HU M351T, F317L
17 (F) 16.6 14.0 440 0 212 100 HU, IFN F311I
18 (M) 16.5 17.3 444 0 68 100 IFN, HU M244V
19 (F) 25.3 16.2 550 0 66 100 IFN M351T
20 (M) 22.4 26.1 245 0 164 100 IFN, HU F317L
BC 21 (F) 55.4 65.6 147 62 1883 100 NA M244V
22 (M) 6.7 17.8 494 51 2188 100 NA WT
23 (M) 33.0 55.7 14 79 2500 100 NA WT
24 (M) 36.7 8.0 21 76 1000 100 NA M351T, D276G
BC = blast crisis; Dg = Diagnosis; F = female; Hr = hematological relapse; HU = hydroxyurea; IF = interpheron alpha; IM = imatinib; M = male; MMR = major
molecular response; PB = peripheral blood; TF = therapy failure; WBC = white blood cell, WT = wild type.
Table 2 Characteristics of patient samples in groups for miR-150 and MYB expression analysis
Disease
stage
Number
of
patients
HU, IFN or
combination
pretreatment
months from
diagnosis
median
(range)
Months on
imatinib
median
(range)
WBC x10
9/L PB median
(range)
PLT x10
9/L PB median
(range)
Blasts in PB
(%)
median
(range)
Ph+ cells
(%)
median
(range)
BCR-ABL (%)
median
(range)
BCR-ABL KD
mutation
Number of
patients
Dg 13 NA NA 67 (22-457) 2 (1-5) 100 132 (61-312) NA
481 (130-824)
AP/BC 12 24 (2-106) 24 (8-55) 34 (1.17-147) 18 (8-76) 100 510
(103-2500)
3
81 (14-562)
Hr 15 18 (1-66) 22 (10-54) 16 (6-28) 10; 12 100 (32-100) 80 (23-827) 15
448 (71-1779)
TF 14 14 (1-68) 18 (12-67) Phy 0 100 (40-100) 32 (11-91) 4
Phy
MMR 16 3 (1-11) 16 (7-24) Phy 0 0 0.02
(0.001-0.1)
NA
Phy
AP = accelerated phase; BC = blast crisis; Dg = Diagnosis; Hr = hematological relapse; MMR = major molecular response; PB = peripheral blood; Phy =
physiological (WBC 4-10 × 10
9/L; PLT 150-400 × 10
9/L ); PLT = platelets; TF = therapy failure; WBC = white blood cell.
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results with respect to RNA quality (RNA integrity
numbers 7.8 - 9.1 and 8.5 - 9.0, respectively) and quan-
tity (mean total RNA amounts 5 ug and 3 ug,
respectively).
MiRVana kit however gave better 230/280 ratio and
therefore was then selected for preparation of samples
for microarrays. Acidic phenol-chloroform extraction
was used for real-time qPCRs, which is a standardized
method in our laboratory for BCR-ABL monitoring in
international scale (IS).
Microarray analysis
PIQOR™ miRXplore arrays (Miltenyi Biotech GmbH,
Cologne, Germany) were used for miRNA expression
profiling and the whole procedure including miRXplore
data analysis (control vs. sample) was performed within
the genomic facility of the manufacturer. Total RNAs
with controlled quality (RIN 8 - 9.2; A260/A280 1.86 -
2.01; A230/A260 1.95 - 2.1) and quantity (1.2 - 4.0 μg)
were sent to Miltenyi Biotech laboratory on dry ice.
RNA quality and quantity was checked after delivery
with the comparable results. Microarray platform con-
tained 872 probes for human miRNAs according to
miRBase version 10.1 and an extensive system of con-
trols. Raw data were derived from ImaGene
® software
(Biodiscovery, El Segundo, USA). Only spots with signal
equal to or higher than 50% percentile of the back-
ground signal intensities were further analyzed.
The complete microarray data were deposited in Gene
Expression Omnibus (GEO) database under the acces-
sion number GSE26260 (http://www.ncbi.nlm.nih.gov/
geo/).
We applied MultiExperiment Viewer (MeV v4.0
release; http://www.tm4.org/mev) for k-means/medians
and hierarchical clustering was performed using average
linkage and average dot product metric.
Real-time qPCRs
Real-time qPCR was performed on RotorGene 6000
(Qiagen, San Francisco, CA, USA). The miRNA expres-
sion assay kits (Applied Biosystems) specific for selected
miRNAs were used to perform reverse-transcriptions
and RT-qPCRs. MiR-30c showed stable expression
across all the patient and control samples analyzed
(stable Ct/ngRNA) and was used as a housekeeping
gene for normalization. Relative fold changes of gene
expression were assessed using 2
-ΔΔCT method. Mean of
ΔCT values of 11 healthy donors was used as a calibra-
tor. Results are presented as expression fold change of a
patient to a healthy control.
TaqMan Gene Expression Assay (product number
Hs00193527; Applied Biosystems) was used for MYB
transcript quantification according to the manufacturer’s
recommendations. The GUS gene was used as the
housekeeping gene with the primer set, probe, and pro-
tocol adopted from Beillard et al. [21].
Prediction of putative miRNA target genes
The TargetScan Human release 5.1. (http://www.targets-
can.org) was used for prediction of miRNA targets.
Visualization and Integrated Discovery (DAVID) (http://
david.abcc.ncifcrf.gov/) [22 , 2 3 ]w a sa p p l i e dt oa n n o t a t e
the biological functions of the predicted targets.
Statistical analyses
Analyses of MYB and miR-150 differential expression
between different groups of samples were conducted
using Kruskall Wallis’st e s ta n dD u n n ’s multiple com-
parison test. Correlation analyses were calculated using
the Spearman’s rho correlation test. Statistical analyses
and graphs were performed using GraphPad Prison ver-
sion 4.03 (GraphPad Software, La Jolla, CA, USA).
Results
miRNA expression profiles in CML
Microarray analysis in CML resulted in the detection of
56 differentially expressed miRNAs (samples vs. con-
trol). Figure 1 shows three main gene clusters (clusters
I, II, III) of altogether 49 miRNAs. A markedly (more
than 1.5 fold; others are not indicated here) increased
level over the control was found in BC pool for miR-
19a, miR-19b, miR-221, miR-126, miR-106a, miR-17,
miR-20a and miR-222 that belong to the cluster I. A
distant gene cluster II grouped down-regulated miRNAs
in BC; more than 1.5 fold change was detected for miR-
24, miR-29b, miR-26b, miR-107, miR-103, miR-150,
miR-451. The cluster III consisted of miRNAs with
increased level in MMR; more than 1.5-fold change was
found for miR-663, miR-638 and miR-720.
A separate cluster was created from MMR and TF
pools and was distant from the cluster grouping Dg
pool together with Hr and BC pools. MMR and TF
pools are represented by the samples from patients dur-
ing the imatinib treatment with optimal response and
failure to achieve CCgR, respectively. The samples from
MMR and TF pools were characterized by physiological
blood count but different BCR-ABL transcript level and
number of Ph+ metaphases (Table 1). The distant clus-
ter of Hr, BC and Dg pools represented CML in pro-
gression and at diagnosis, respectively.
Validation of array data and sample pooling
Eight up-regulated (miR-19a, miR-19b, miR-221, miR-
222, miR-126, miR-106a, miR-17 and miR-20a) and 3
down-regulated miRNAs (miR-103, miR-150 and miR-
451) with more than 2.0-fold change in their expres-
sion (see Figure 1) over the control were selected for
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cision by the RT-qPCR. MiRNAs expressions were
measured in the pools and in individual samples of
each pool. The heatmaps showed comparable results
(Figure 2); on comparing array and RT-qPCR data of
pools and averaged RT-qPCR data of individuals, hier-
archical clustering formed similar gene and sample
clusters. We noted also few discrepancies e.g. for miR-
126 and miR-451. We evaluated RT-qPCR data of each
sample using hierarchical clustering (Figure 3). Seven
miRNAs (miR-181a, miR-181b, miR-92a, miR-146a,
let7c, miR-144, miR-155) that were not displayed in
Figure 1 and 2 due to low signal on the array analysis
in at least one of the pools, were included into the
RT-qPCR analysis because of strong change in their
expressions in BC pool. Three prominent patient clus-
ters and three prominent miRNA clusters were identi-
fied (Figure 3). Firstly, a gene cluster distant from the
other two consisted of miR-103, miR-150, miR-451
and miR-144. These molecules showed a rather
decreased level at Dg, in Hr and BC. The other two
closely related clusters consisted of miR-19b, miR-19a,
miR-17, miR-20a, miR-92a, miR-106a, miR-222, miR-
126, miR-146a, miR-181a, miR-181b, let7c, miR-155
and miR-221 that were up-regulated in BC samples.
The BC samples formed one cluster that was mixed
with two samples from hematological relapse (Hr 4, 5),
one from diagnosis (Dg 3) and one therapy failure (TF
4). This cluster was related to the cluster that was
formed by Hr samples (Hr 1-3), two Dg samples (Dg 1,
4) and one therapy failure (TF 3). The third cluster
Figure 1 Hierarchical clustering analysis of expression data of
49 microRNAs from microarray analysis. Seven miRNAs are not
displayed due to signal at the background level in at least one of
the pools analyzed.
A.
B.
C.
Figure 2 Hierarchical clustering analysis of miRNA expression
data. (A.) microarray - pools, (B.) real-time qPCR - pools and (C.)
real-time qPCR - individual samples.
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ples, three TFs (TF 1, 2, 5) and was mixed with Dg 2
sample.
Target in silico analyses and functional annotation
The putative target genes were selected for 17 miRNAs
with validated expression in different phases of CML
(Figure 3). The predicted targets containing highly con-
served sites were further studied according to the PCT
values [24] from the TargetScan release 5.1 except for
miR-106a because of lack data in the database. Because
the PCT values are available only in the TargetScan we
did not use another databases for miR-106a target pre-
diction to preserve data consistency.
The targets were selected according to PCT equal or
higher than 0.1 and 0.5 of miRNAs with low and high
number of targets in the database, respectively (see
Additional file 1: Table S1). The PCT, ranging between 0
and 1, corresponds to a Bayesian estimate of the prob-
ability that a site conserved to a particular branch length
is conserved due to miRNA targeting [24]. The 30% of
all of the targets with only conserved sites (Additional
f i l e1 :T a b l eS 1 )a r ep u t a t i v et a r g e tg e n e so fm o r et h a n
one of the selected miRNAs.
Functional annotation analysis of predicted targets
(Table 3) revealed several biological processes (P <
0.0001). The encoded proteins are involved mainly in
the regulation of transcription, intracellular signaling
cascades, amino acid phosphorylation, regulation of
RNA metabolic processes, regulation of apoptosis, regu-
lation of cell proliferation and protein transport. Several
proteins are implicated in hematopoietic or lymphoid
organ development (n = 52; e.g. BMI1, WNT3A, MLL5,
IL25, CDK6, MYH9, BCL2L11, CRKL, KIT, BCL2,
RUNX1, TCF3, PIK3R1, NOTCH2, PKNOX1, SP1, SP3,
TGFBR3), regulation of erythrocyte differentiation
( A C V R 2 A ,A C V R 1 B ,E T S 1 ,M A F B ,S P I 1 ,C D K 6 ,
FOXO3, INPP5D, ARNT) and regulation of myeloid cell
differentiation (ZFP36, HMGB3, MAFB, KLF10,
NDFIP1, SPI1, CDK6, FOXO3, PRDM16, PURB, ARNT,
LIF, ACVR1B, ACVR2A, ID2, ETS1, GNAS, INPP5D,
RUNX1).
Using KEGG database [25] we analyzed signaling
pathways with significant hits (P < 0.0001) for predicted
targets involved in endocytosis (hsa04144), pathways in
cancer (hsa05200), mTOR signaling pathway (hsa04150),
hedgehog signaling pathway (hsa04340), chronic myeloid
leukemia (hsa05220), focal adhesion (hsa04510) and
Wnt signaling (hsa04310) (Table 3).
Table 4 summarizes predicted targets associated with
chronic myeloid leukemia. Most of them are involved in
MAPK signaling (BCR, E2F2, E2F3, CBL, RAF1, CRK,
CRKL, KRAS, SOS1, MAPK1). TGBR2, SMAD4 and
ACVR1B play a role in transforming growth factor beta
signaling pathway. Cyclin D1 (CCND1) and cyclin-
dependent kinase 6 (CDK6) are important for the cell
cycle and in the p53 pathway. Cell cycle is influenced by
cyclin-dependent kinase inhibitor 1B (p27). ErbB
Figure 3 Hierarchical clustering analysis of detected levels of 17 selected miRNAs by real-time qPCRs.
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GO category Count % * P-value
Biological process
Regulation of transcription 407 22.0 4.28E-20
Intracellular signaling cascade 208 11.24 5.52E-12
Protein amino acid phosphorylation 127 6.86 2.03E-11
Regulation of RNA metabolic process 269 14.54 5.67E-10
Negative regulation of cellular biosynthetic process 107 5.78 8.68E-10
Phosphate metabolic process 159 8.59 7.5E-9
Regulation of small GTPase mediated signal transduction 58 3.14 1.41E-8
Regulation of Ras protein signal transduction 51 2.8 1.89E-8
Regulation of apoptosis 132 7.1 1.35E-7
Vesicle-mediated transport 101 5.5 2.2E-7
Negative regulation of signal transduction 50 2.7 2.77E-7
Protein transport 124 6.7 5.48E-7
Transmembrane receptor protein tyrosine kinase signaling pathway 49 2.65 1.04E-6
Regulation of cell migration 40 2.16 1.57E-6
Positive regulation of cell differentiation 49 2.65 2.03E-6
Intracellular transport 108 5.84 2.04E-6
Regulation of cell proliferation 124 6.7 2.99E-6
Hematopoietic or lymphoid organ development 52 2.8 7.41E-6
Regulation of protein kinase cascade 47 2.5 9.5E-5
Regulation of protein kinase activity 60 3.24 1.05E-4
Regulation of erythrocyte differentiation 9 0.5 2.41E-4
Regulation of myeloid cell differentiation 19 1.2 2.42E-4
Molecular function
Transcription regulator activity 268 14.5 8.81E-19
GTPase regulator activity 82 4.4 1.32E-8
Protein kinase activity 110 5.95 2.33E-8
Cytoskeletal protein binding 90 4.86 1.06E-6
Transcription repressor activity 63 3.41 1.46E-6
Protein domain specific binding 65 3.51 1.67E-6
DNA binding 314 16.97 2.51E-6
Zinc ion binding 303 16.38 3.7E-5
Chromatin binding 34 1.84 4.03E-5
Cation binding 509 27.51 1.28E-4
SH3 domain binding 24 1.3 1.51E-4
Pathway
Endocytosis 45 2.43 1.93E-8
Pathways in cancer 64 3.46 1.41E-7
mTOR signaling pathway 16 0.86 1.13E-4
Hedgehog signaling pathway 16 0.86 2.82E-4
Chronic myeloid leukemia 19 1.03 3.21E-4
Focal adhesion 37 2.0 3.39E-4
Wnt signaling pathway 29 1.57 8.77E-4
* from total 1850
Major Gene Ontology (GO) categories. The threshold of statistical significance for GO enrichment in the gene list was set up to P ≤ 10
-4.
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RUNX1 known as AML1 contributed to the abnormality
in growth inhibition.
MiR-150 down-regulation and targeted MYB
overexpression
Dramatic reduction of miR-150 in BC, at Dg and in Hr
and its normal levels in patients under imatinib treat-
ment (MMR and TF) (Figure 3) prompted us to deter-
mine this expression pattern on a larger cohort of
patients (n = 70; Table 2). Significant down-regulation
of the miRNA (p < 0.05) in comparison to healthy con-
trols (n = 11) was confirmed for diagnosis and pro-
gressed phases of CML (Figure 4A.). MiR-150 level
decreased more than 2-fold in 67% of hematological
relapses (n = 10/15). There was no significant change in
MMR and TF compared to controls. Among all patient
samples analyzed, we found significant inverse correla-
tion of miR-150 expression with BCR-ABL transcript
level (p = 0.01; r = -0.501). To test whether miR-150 is
regulated by BCR-ABL we have used a Ph+ cell line
MOLM-7 and incubated it with two concentrations of
Table 4 Target annotation in pathways of chronic myeloid leukemia (hsa05220)
microRNAs Targets* Definition PCT Pathway in CML
miR-20a BCR Breakpoint cluster region protein 0.56
miR-222 E2F2 E2F transcription factor 2 0.32
miR-17 E2F2 0.59
miR-155 E2F2 0.78
miR-17 E2F3 E2F transcription factor 3 0.54
miR-150 CBL E3 ubiquitin-protein ligase 0.45
miR-222 CBL 0.33
miR-155 CBL 0.67
miR-19a RAF1 RAF proto-oncogene serine/threonine-protein kinase 0.82 MAPK signaling
miR-126 CRK Proto-oncogene C-crk 0.55
miR-17 CRK 0.88
miR-221 CRKL Proto-oncogene C-crk 0.16
miR-19a KRAS GTPase 0.92
miR-155 KRAS 0.33
miR-155 SOS1 Son of sevenless 0.53
miR-181a SOS1 0.78
miR-19a MAPK1 Extracellular signal-regulated 0.86
miR-17 MAPK1 kinase 1/2 (ERK) 0.96
miR-19a TGFBR2 Transforming growth factor -beta 0.87
miR-144 TGFBR2 receptor type-2 0.65
miR-155 TGFBR2 0.28 Transforming growth factor ß
miR-144 SMAD4 Mothers against DPP homolog 4 0.58
miR-17 ACVR1B Transforming growth factor -beta receptor type-1 0.52
miR-19 CCND1 Cyclin D1 0.86
miR-17 CCND1 0.97 p53 pathway
miR-155 CCND1 0.55
miR-103 CDK6 Cyclin-dependent kinase 6 0.73
miR-222 CDKN1B Cyclin-dependent kinase inhibitor 1B (p27) 0.50 Cell cycle
miR-103 PIK3R1 Phosphoinositide-3-kinase, 0.73
miR-221 PIK3R1 regulatory subunit 0.63
miR-155 PIK3R1 0.28 ErbB signaling
miR-19a PIK3R3 Phosphoinositide-3-kinase, 0.92
miR181a PIK3R3 regulatory subunit 0.81
miR-17 RUNX1 Runt-related transcription factor 1 0.88 Abnormality in
miR-144 RUNX1 (AML1) 0.59 growth inhibition
* official gene symbol
Machová Poláková et al. Molecular Cancer 2011, 10:41
http://www.molecular-cancer.com/content/10/1/41
Page 8 of 13imatinib (1uM and 10 uM, Additional file 2: Figure S1A)
for total 48 hours. We observed that following reduction
of BCR-ABL tyrosine kinase activity (exemplified by
decreased intensity of p-CRKL (Additional file 2: Figure
S1B)) by imatinib the miR-150 levels were significantly
upregulated. This paragraph provides link between levels
of one particular microRNA, miR-150, identified by our
microarray analysis and CML pathogenesis.
MYB is a confirmed target of miR-150 [16]. The
expression pattern of MYB during the course of CML
has not as yet been reported. We decided to analyze
MYB transcript levels in the same cohort of patients.
MYB was significantly increased at Dg, in AP/BC and
Hr in comparison to controls (p < 0.001), to MMR (p <
0.05) and to TF (p < 0.05). Spearman’sr h oa n a l y s i sd i s -
played significant inverse correlation of MYB with miR-
150 expression (p = 0.01; r = -0.521) and significant
positive correlation between MYB expression and BCR-
ABL transcript level (p = 0.01; r = 0.771).
Discussion
Specific microRNAs regulate hematopoietic cell differen-
tiation and development [26]. The main interest is in
whether there exists a link between levels of miRNAs
and leukemia pathogenesis. The first work dealing with
miRNA expression in CML demonstrated enhanced
expression of the miR-17-92 cluster in CML CD34+
cells [11]. Other works that reported miRNA aberrant
expression in CML appeared very recently. For example,
it demonstrated that several miRNAs dysregulated in
CML (miR-150, miR-146a, miR-142-3p, miR-199b-5p)
were rapidly restored under imatinib treatment [14].
Several miRNAs (e.g. miR-191, miR-29a, miR-422b,
miR-100, miR-326, miR-26a) are promising predictors of
imatinib resistance in newly diagnosed CML patients
[13].
This study investigates microRNA differential expres-
sion profiles that were initially analyzed at different
stages of CML using microarrays. Pooling of patient
samples was applied for microarray analysis to reduce
individual variability and to find common features of the
disease.
MiRNA array data showed similar expression pattern
of 49 miRNAs in imatinib responders with MMR and
patients with failure to achieve complete cytogenetic
response. As expected, hierarchical clustering assembled
the pools of samples at diagnosis, in hematological
relapse and blast crisis, while MMR and TF pools
formed a separate cluster (Figure 1). Total leukocytes
from blast crisis peripheral blood that consisted of more
than 50% blasts of each sample in the pool showed the
highest number of strongly deregulated miRNAs.
We applied the functional annotation tool DAVID to
look for the biological functions of predicted targets
with only conserved sites and high PCT values of the 17
miRNAs with real-time qPCR-confirmed up-regulation
(miR-19a, miR-19b, miR-17, miR-20a, miR-92a, miR-
221, miR-222, miR-126, miR-146a, miR-181a, miR-181b,
let7c and miR-155) and down-regulation (miR-103,
miR-150, miR-451 and miR-144) in blast crisis (Figure
3). Several targets were involved in the processes that
were found to be important in CML; endocytosis [27],
mTOR signaling pathway [28,29], hedgehog signaling
[30,31], focal adhesion [32,33] and Wnt signaling
[34,35]. We summarized 19 genes with the probability
to be targeted by miR-20a, miR-17, miR-19a, miR-103,
Dg AP/BC Hr TF MMR CONT
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0.1
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2
-
C
T
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miR-150 MYB
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**
**
***
***
**
***
***
***
***
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Figure 4 Expression analysis of miR-150 (A.) and its target MYB (B.) in different phases of CML in comparison to control (CONT). CONT
= 11, Dg = 13 diagnosis, AP/BC = 12 accelerated phase/blast crisis, Hr = 15 hematological relapse, TF = 14 therapy failure (failure to achieve
complete cytogenetic remission), MMR = 16 major molecular response. *** P < 0.001;
** P < 0.01; * P < 0.05
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Page 9 of 13miR-144, miR-150, miR-155, miR-181a, miR-221 and
miR-222. The encoded proteins were annotated in path-
ways related to the CML (hsa05220). Out of these, 10
targets are involved in MAPK signaling (BCR, E2F2,
E 2 F 3 ,C B L ,R A F 1 ,C R K ,C R K L ,K R A S ,S O S 1 ,M A P K 1 ) .
Interestingly, inhibition of MAPK signaling in Ph+ cell
line K562 induced apoptosis [36]. Application of MAPK
specific inhibitor U0126 showed synergistic effect with
imatinib resulting in CD34+ progenitor reduction in
CML [36].
Confirmed increase of miR-19a, miR-19b, miR-17,
miR- 20a, miR-92a, miR-106a, miR-221, miR-222, miR-
126, miR-146a, miR-181a, miR-181b, let7c and miR-155
was identified in samples of BC pool (Figure 3). This
pattern was not found in Dg, Hr, TF or MMR pools.
Overexpression of these miRs may be related to the
immature character of blasts. Whether the increased
level of these miRNAs may contribute to the CML
pathogenesis or may simply reflect the stage of the dis-
ease is the matter of further investigation. Abnormal
expression of onkomir miR-17-92 (miR-17; miR-19a;
miR-19b; miR-20a; miR-92a) was described in CML
CD34+ cells [11]. Agirre et al. [12] found up-regulated
miR-221 and miR-222 in mononuclear cells of CML
patients in comparison to healthy controls. MiR-155,
miR-106a, miR-146a, miR-181 and miR-126 were
reported as deregulated miRNAs in CML [13,14]. To
our knowledge, let7c expression has so far not been
described in CML. In this study, our in silico analyses
revealed that miR-221 and miR-103 (PCT 0.63 and 0.73,
respectively) target PIK3R1. PIK3R3 is predicted to be
regulated by miR-19a and miR-181a (PCT 0.92 and 0.81,
respectively). PI3K is annotated in ERBB, MAPK and
mTOR signaling pathways. KRAS, which is involved in
MAPK signaling, is a predicted target of miR-19a (PCT
0.92). MAPK expression may be regulated by onkomirs
miR-17 and miR-19a (PCT 0.96 and 0.86, respectively).
Interestingly, it was reported that RAS/MAPK signaling
may contribute to the survival of BCR-ABL positive
cells under imatinib selection pressure [37]. AKT1, a
member of the antiapoptotic PI3K pathway, is involved
in both, BCR-ABL mediated transformation as well as in
response to the BCR-ABL kinase inhibitors. It was
shown that the PI3K/AKT/mTOR signaling is activated
in imatinib naive cells while under imatinib pressure it
may enhance resistance to imatinib [38]. As shown in
our real-time qPCR data (Figure 3), the rather decreased
levels of miR-181a, miR-221 and miR-19a in some ima-
tinib treated patients, and miR-103 down-regulation in a
number of blast crisis, diagnosis and progressed CML
may contribute to the increased level of PI3K and thus
may be involved in the previously described PI3K/AKT/
mTOR signaling activation and in the resistance devel-
opment in some CML cases. Though no experimental
therapy using miRNA modulation has as yet provided
significant and curative approach, the knowledge of
deregulation of miRNAs specific for CML may facilitate
the development of such therapeutic strategies. Several
candidate microRNAs (e.g. miR-181a, miR-221, miR-
19a, miR-103) regulating expression in CML target
important signaling pathways may represent promising
candidate targets for CML therapy.
The real-time qPCR validated the down-regulation of
miR-150, miR-451, miR-103 and miR-144 overall in
individual samples of BC, Hr, Dg pools and in some
samples of TF pool (Figure 3). These molecules may be
related to the CML pathogenesis and may reflect trans-
formation from chronic to accelerated phases. Agirre et
al. found miR-150 downregulation in mononuclear cells
and CD34+ cells separated from bone marrow in newly
diagnosed CML patients (n = 6) in comparison to
healthy donors (n = 6) [12]. MiR-150 was recently
described to be downregulated in untreated CML
patients [14]. Flamant et al. [14] suggest that miR-150
play a role in leukemic cells and potentially in the more
primitive hematopoietic compartment in chronic phase
CML patients. This is in line with the knowledge that
miR-150 is important in the regulation of hematopoiesis.
During normal erythroid differentiation its level is gra-
dually decreased [39], however; it shows the highest
expression in mature lymphocytes [40]. Others proved
that miR-150 expression increases during B-lymphoid
differentiation in contrast to myeloid differentiation. It
seems likely that miR-150 regulates the development of
other two different blood lineages; B lymphocytes and
megakaryocytes [41,42]. Thus, miR-150 deregulation is
found in hematological malignancies; miR-150 is
decreased in polycytemia vera reticulocytes [43] and a
marked decrease was recently also detected in MDS-del
(5q) [44] while, in contrast, a twofold increase was
found in CLL lymphocytes [45].
Based on our results [15] and recent results of others
we expanded real-time qPCR assays of miR-150 on the
larger cohort of CML patients. Decreased level of miR-
150 was confirmed in patients at diagnosis, in the
majority of patients with hematological relapse and in
accelerated phase and blast crisis. Normal miR-150 level
was observed in imatinib treated patients with major
molecular response and failure to achieve CCgR. Our
observations are consistent with the data of Flamant et
al. [14] showing rapid increase of miR-150 expression
after imatinib treatment initiation in patients with newly
diagnosed CML. They further found that low miR-150
expression inversely correlated with white blood count
and thus speculated that the level reflected the high leu-
kocyte counts in newly diagnosed CML patients. We
showed here a significant inverse correlation of miR-150
expression with BCR-ABL transcript level (p = 0.01; r =
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Page 10 of 13-0.501). Non-treated newly diagnosed patients, patients
with disease progression and resistant to imatinib
showed a high level of BCR-ABL together with high leu-
kocyte count and decreased amount of miR-150. Normal
miR-150 level was detected in imatinib responders
(MMR) and patients with failure to achieve CCgR (TF)
with normal blood count and low BCR-ABL transcript
level. As imatinib targets Ph+ cells, the normal level of
miR-150 in imatinib treated patients in chronic phase
with physiological blood count could be the result of
the suppression of leukemic cells and the concomitant
recovery of normal hematopoiesis under imatinib treat-
ment. Our in vitro t e s t ss h o w e de l e v a t e de x p r e s s i o no f
miR-150 and marked decrease of p-CRKL following
imatinib in vitro treatment of Ph+ cell line MOLM-7.
These findings suggest a potential functional relation-
ship between miR-150 and BCR-ABL.
Gene expression of MYB in our study showed a signif-
icant inverse correlation with miR-150 transcript level (p
= 0.01; r = -0,409). MYB is the proven target of miR-150
and encodes a transcriptional factor required for prolif-
eration and survival of normal and leukemic blast cells.
A recently published study on a mouse model of blast
crisis reported that c-MYB is required for BCR-ABL
dependent leukemogenesis [46]. Lidonnici et al. [46]
speculated that miR-150 reduction might contribute to
the c-MYB upregulation that is likely induced by BCR-
ABL, and may be involved in BCR-ABL driven leukemo-
genesis in CML. Interestingly, we found a significant
correlation between MYB expression and BCR-ABL
transcript level (p = 0.01; r = 0,782) in CML patients,
which is in line with the above described suggestion.
In summary, our data demonstrated that miR-150, miR-
20a, miR-17, miR-19a, miR-103, miR-144, miR-155, miR-
181a, miR-221 and miR-222 are deregulated in CML.
Furthermore, in silico filtering identified targeted genes
that are involved in cell cycle, growth inhibition, MAPK,
ErBb, transforming growth factor beta and p53 signaling
pathways that are reported in CML pathogenesis. MiR-
150 expression showed significant negative correlation
with its target MYB and with BCR-ABL transcript level.
The results of this study outline the mechanisms whereby
miRNAs may be implicated in CML pathogenesis. How-
ever, if they function in BCR-ABL dependent or indepen-
dent manner has to be elucidated.
Additional material
Additional file 1: Table S1: Number of predicted targets of
conserved miRNA families. Table summarizes number of the microRNA
targets that were selected according to PCT equal or higher than 0.1 and
0.5.
Additional file 2: Figure S1: MiR-150 exression is elevated and BCR-
ABL activity is dropped after imatinib treatment in Ph+ MOML-7
cells. Data from in vitro test of miR-150 expression change after Ph+ cell
line incubation with imatinib. (A.) MiR-150 expression change after
imatinib treatment in Ph+ MOML-7 cells. 3 × 10
6 MOLM-7 cells were
incubated for 24 or 48hrs with or without (white bars; CTRL = control)
imatinib. Two different concentrations of imatinib were tested (1 μM-
gray bars and 10 μM - black). Cellular RNA was isolated by Trizol
(Invitrogen), transcribed using High Capacity cDNA Reverse Transcription
Kit (Roche Diagnostics). Real-time qPCR was performed using TaqMan
protocol (Roche Diagnostics) and was run on the ABI 7900HT instrument.
RNU44 was used as housekeeping gene. Data were evaluated by 2
-ΔCt
method. The viability of culture with imatinib decreased: 1 μM imatinib-
from 94% after 24hrs to 21% after 48hrs; 10 μM imatinib- from 95% after
24hrs to 18% after 48hrs. (B.) The intensity change of p-CRKL after
imatinib treatment in Ph+ MOLM-7 cells. The amount of p-CRKL (a client
molecule of BCR-ABL tyrosine kinase) was measured by standard western
blot analysis (p-CRKL (Tyr207) antibody; Cell Signaling Technology) after
24h culture cultivation with imatinib using both concentrations. Beta-
actin (monoclonal antibody Anti-beta-Actin, Sigma) was used as the
loading control and was measured by western blot analysis using
alkaline phosphatase. The measurement of p-CRKL was not possible to
perform in the culture after 48 incubation due to a marked viability
decrease and thus to low amount of material.
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